Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years

INTRODUCTION: Most patients with HER2-positive breast cancer receive chemotherapy and trastuzumab. Data from adjuvant trials have shown that the combination of docetaxel, carboplatin and weekly trastuzumab (TCH) is well tolerated and as effective as anthracycline-containing regimes. Previous investi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Breast Care (Basel)
Huvudupphovsmän: Kolberg, Hans-Christian, Akpolat-Basci, Leyla, Stephanou, Miltiades, Aktas, Bahriye, Hannig, Carla Verena, Liedtke, Cornelia
Materialtyp: Artigo
Språk:Inglês
Publicerad: S. Karger GmbH 2016
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5123029/
https://ncbi.nlm.nih.gov/pubmed/27920624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000452079
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk